Literature DB >> 12472474

Squamous cell carcinoma and adenocarcinoma of the lower third of the esophagus and gastric cardia: similarities and differences.

A Alexandrou1, P A Davis, S Law, S Murthy, B P Whooley, J Wong.   

Abstract

Squamous cell carcinoma (SCC) and adenocarcinoma (ADC) of the lower esophagus and gastric cardia were compared in their clinical features and long-term prognosis. Two hundred and ninety-five patients with SCC and 263 with ADC were reviewed. Resectability rates for SCC and ADC were 74.2% and 73.2% respectively (P=0.8). Among those who underwent resection, ADC was more advanced, with 22.3% at stage IV compared with 7.4% for SCC (P=0.001). Postoperative cardiac events occurred in 24.2% of SCC patients and 14.7% of ADC patients (P=0.015), and major respiratory complications in 20.1% and 8.6% respectively (P=0.001). Thirty-day mortality rates were 2.7% and 4% (P=0.46), and hospital mortality rates were 11.4% and 7.6% (P=0.19). Median survival rates were 12.5 months for SCC and 11.6 months for ADC (P=0.99) and 5-year survival rates were 19.9% and 17.6% (P=0.55) respectively. Squamous cell carcinoma of the lower esophagus and ADC of the cardia differed in patient demographics and clinical features but long-term prognoses were similar.

Entities:  

Mesh:

Year:  2002        PMID: 12472474     DOI: 10.1046/j.1442-2050.2002.00272.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  7 in total

Review 1.  Neoadjuvant treatment of esophageal cancer.

Authors:  Nicholas P Campbell; Victoria M Villaflor
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

2.  Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma.

Authors:  Christophe Mariette; Laetitia Finzi; Guillaume Piessen; Isabelle Van Seuningen; Jean Pierre Triboulet
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

Review 3.  Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging.

Authors:  Jennifer Q Zhang; Craig M Hooker; Malcolm V Brock; James Shin; Sue Lee; Remealle How; Noreli Franco; Helen Prevas; Alicia Hulbert; Stephen C Yang
Journal:  Ann Thorac Surg       Date:  2012-02       Impact factor: 4.330

4.  The prognostic significance of celiac lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.

Authors:  Yen-Hao Chen; Hung-I Lu; Yu-Ming Wang; Chien-Ming Lo; Shang-Yu Chou; Cheng-Hua Huang; Li-Hsueh Shih; Su-Wei Chen; Shau-Hsuan Li
Journal:  Oncotarget       Date:  2017-10-16

5.  SDF-1α predicts poor prognosis in patients with locally advanced esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy.

Authors:  Yen-Hao Chen; Hung-I Lu; Yu-Ming Wang; Chien-Ming Lo; Shang-Yu Chou; Shau-Hsuan Li
Journal:  Biomed J       Date:  2021-05-19       Impact factor: 7.892

Review 6.  Evolving treatment paradigms in esophageal cancer.

Authors:  Ilit Turgeman; Irit Ben-Aharon
Journal:  Ann Transl Med       Date:  2021-05

7.  High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis.

Authors:  Xin Sun; Lei Wang; Yang Wang; Jingjing Kang; Wei Jiang; Yu Men; Zhouguang Hui
Journal:  Front Oncol       Date:  2020-08-04       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.